Skip to main content

Advertisement

SpringerLink
Log in

Drei neue IL-23p19- und ein neuer IL-17A/F-Hemmer

Therapie der Psoriasis

  • Fortbildung
  • Published:
hautnah dermatologie Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Literatur

  1. Reich K et al. Five-year maintenance of clinical response and improvements in health-related quality of life in patients with moderate-to-severe psoriasis treated with guselkumab: results from VOYAGE 1 and VOYAGE 2. Br J Dermatol. 2021; 185: 1146-59

  2. Thaçi D et al. Five-year efficacy and safety of tildrakizumab in patients with moderate-to-severe psoriasis who respond at week 28: pooled analyses of two randomized phase III clinical trials (reSURFACE 1 and reSURFACE 2). Br J Dermatol 2021; 185: 323-34

  3. Papp KA et al. Long-term efficacy and safety of risankizumab for the treatment of moderate-to-severe plaque psoriasis: interim analysis of the LIMMitless open-label extension trial beyond 3 years of followup. Br J Dermatol 2021; 185: 1135-45

  4. Gordon KB et al. Bimekizumab efficacy and safety in moderate to severe plaque psoriasis (BE READY): a multicentre, double-blind, placebo-controlled, randomised withdrawal phase 3 trial. Lancet 2021; 397: 475-86

  5. Reich K et al. Bimekizumab versus ustekinumab for the treatment of moderate to severe plaque psoriasis (BE VIVID): efficacy and safety from a 52-week, multicentre, double-blind, active comparator and placebo controlled phase 3 trial. Lancet. 2021; 397: 487-98

  6. Warren RB et al. Bimekizumab versus Adalimumab in Plaque Psoriasis. N Engl J Med 2021; 385: 130-41

  7. Reich K et al. Bimekizumab versus Secukinumab in Plaque Psoriasis. N Engl J Med 2021; 385: 142-52

Download references

Author information

Authors and Affiliations

  1. Klinik für Dermatologie und Psoriasis-Zentrum, Univ.-Klinikum Schleswig-Holstein/Campus Kiel, Kiel, Deutschland

    Ulrich Mrowietz

Authors
  1. Ulrich Mrowietz
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ulrich Mrowietz.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Mrowietz, U. Therapie der Psoriasis. hautnah dermatologie 38 (Suppl 1), 24–27 (2022). https://doi.org/10.1007/s15012-021-6827-1

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s15012-021-6827-1

Search

Navigation